StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Saturday. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reissued an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

NSPR opened at $2.40 on Friday. InspireMD has a one year low of $1.81 and a one year high of $3.48. The stock has a market cap of $59.83 million, a price-to-earnings ratio of -3.24 and a beta of 0.93. The stock’s 50 day moving average price is $2.64 and its 200-day moving average price is $2.57.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The business had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the previous year, the business earned ($0.24) EPS. As a group, analysts predict that InspireMD will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to its most recent filing with the SEC. The firm purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.